Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations

Background: Budesonide has a long history as intranasal drug, with many marketed products. Efforts should be made to demonstrate the therapeutic equivalence and safety comparability between them. Given that systemic availability significantly varies from formulations, the clinical comparability of diverse products comes to be of clinical interest and a regulatory requirement. The aim of the present study was to compare the systemic availability, pharmacodynamic effect, and safety of two intranasal budesonide formulations for the treatment of rhinitis. Methods: Eighteen healthy volunteers participated in this randomised, controlled, crossover, clinical trial. On two separated days, subjects received a single dose of 512 mu g budesonide (4 puffs per nostril) from each of the assayed devices (Budesonida nasal 64 (R), Aldo-Union, Spain and Rhinocort 64 (R), AstraZeneca, Spain). Budesonide availability was determined by the measurement of budesonide plasma concentration. The pharmacodynamic effect on the hypothalamic-adrenal axis was evaluated as both plasma and urine cortisol levels. Adverse events were tabulated and described. Budesonide availability between formulations was compared by the calculation of 90% CI intervals of the ratios of the main pharmacokinetic parameters describing budesonide bioavailability. Plasma cortisol concentration-time curves were compared by means of a GLM for Repeated Measures. Urine cortisol excretion between formulations was compared through the Wilcoxon's test. Results: All the enroled volunteers successfully completed the study. Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUCi (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4). The pharmacodynamic effects, measured as the effect over plasma and urine cortisol, were also comparables between both formulations. No severe adverse events were reported and tolerance was comparable between formulations. Conclusion: The systemic availability of intranasal budesonide was comparable for both formulations in terms of most pharmacokinetic parameters. The pharmacodynamic effect on hypothalamic-pituitary-adrenal axis was also similar. Side effects were scarce and equivalent between the two products. This methodology to compare different budesonide-containing devices is reliable and easy to perform, and should be recommended for similar products intented to be marketed or already on the market.

Das europäisches Netzwerk zur Koordination der Altersbestimmung bei Fischen: European Fish Ageing Network (EFAN)

Financial support is going to be applied for from the European Commission in order to establish the European Fish Ageing Network (EFAN). The project, which was planned and initiated from Norway (Floedevigen) is supposed to be a concerted action from 14 European Countries involving about 35 institutions. The primary aim of the network is to coordinate the research in age reading, especially the improvement of data bases for reference material, the transformation of research (e.g. daily ring formation in otoliths) to each interested reader. Moreover, the applied financial support is supposed to be preliminary spent for travel of researcher and technicians to other institutes where the same fish species are aged. Reference material is supposed to be sent to the institutes for check-reading. Specific workshops will be held in cases where heterogeneous results occur from check-reading the reference material.

Never-resting microglia: physiological roles in the healthy brain and pathological implications

Microglia are largely known as the major orchestrators of the brain inflammatory response. As such, they have been traditionally studied in various contexts of disease, where their activation has been assumed to induce a wide range of detrimental effects. In the last few years, a series of discoveries have challenged the current view of microglia, showing their active and positive contribution to normal brain function. This Research Topic will review the novel physiological roles of microglia in the developing, mature and aging brain, under non-pathological conditions. In particular, this Research Topic will discuss the cellular and molecular mechanisms by which microglia contribute to the formation, pruning and plasticity of synapses; the maintenance of the blood brain barrier; the regulation of adult neurogenesis and hippocampal learning; and neuronal survival, among other important roles. Because these novel findings defy our understanding of microglial function in health as much as in disease, this Research Topic will also summarize the current view of microglial nomenclature, phenotypes, origin and differentiation, sex differences, and contribution to various brain pathologies. Additionally, novel imaging approaches and molecular tools to study microglia in their non-activated state will be discussed. In conclusion, this Research Topic seeks to emphasize how the current research in neuroscience is challenged by never-resting microglia.

Epitope mapping of antibodies to alpha-synuclein in LRRK2 mutation carriers, idiopathic Parkinson disease patients, and healthy controls

Alpha-synuclein (Snca) plays a major role in Parkinson disease (PD). Circulating anti-Snca antibodies has been described in PD patients and healthy controls, but they have been poorly characterized. This study was designed to assess the prevalence of anti-Snca reactivity in human subjects carrying the LRRK2 mutation, idiopathic PD (iPD) patients, and healthy controls and to map the epitopes of the anti-Snca antibodies. Antibodies to Snca were detected by ELISA and immunoblotting using purified recombinant Snca in plasma from individuals carrying LRRK2 mutations (104), iPD patients (59), and healthy controls (83). Epitopes of antibodies were mapped using recombinant protein constructs comprising different regions of Snca. Clear positive anti-Snca reactivity showed no correlation with age, sex, years of evolution, or the disability scores for PD patients and anti-Snca reactivity was not prevalent in human patients with other neurological or autoimmune diseases. Thirteen of the positive individuals were carriers of LRRK2 mutations either non-manifesting (8 out 49 screened) or manifesting (5 positive out 55), three positive (out of 59) were iPD patients, and five positive (out of 83) were healthy controls. Epitope mapping showed that antibodies against the N-terminal (a.a. 1-60) or C-terminal (a.a. 109-140) regions of Snca predominate in LRRK2 mutation carriers and iPD patients, being N122 a critical amino acid for recognition by the anti-C-terminal directed antibodies. Anti-Snca circulating antibodies seem to cluster within families carrying the LRRK2 mutation indicating possible genetic or common environmental factors in the generation of anti-Snca antibodies. These results suggest that case-controls' studies are insufficient and further studies in family cohorts of patients and healthy controls should be undertaken, to progress in the understanding of the possible relationship of anti-Snca antibodies and PD patholog

Análise do efeito do envelhecimento e da doença pulmonar obstrutiva crônica sobre a limitação ao fluxo expiratório por meio da técnica de pressão expiratória negativa

O termo limitação ao fluxo expiratório (LFE) refere-se a uma condição na qual o fluxo expiratório máximo obtido durante um ciclo da respiração espontânea é menor que o previsto e permanece constante apesar do aumento do gradiente pressórico. A LFE pode estar presente durante o envelhecimento pulmonar fisiológico, e em afecções pulmonares obstrutivas, como na doença pulmonar obstrutiva crônica (DPOC). A aferição direta para determinar a LFE requer a mensuração do volume pela relação entre o fluxo e a pressão transpulmonar, porém é um método invasivo. Os testes usualmente empregados estão baseados na comparação da curva fluxo-volume expiratório máximo e corrente, porém estas técnicas requerem alto grau de colaboração do indivíduo e podem gerar alteração do tônus muscular brônquico. Estudos sugerem que a Técnica de Pressão Expiratória Negativa (NEP) pode ser aplicada para detecção da LFE, sendo um método simples, não invasivo e que não requer esforço dos voluntários. Contudo, índices quantitativos para a avaliação deste fenômeno ainda não foram definidos, assim como também não foram estudadas a LFE no processo de envelhecimento e nos diversos estágios de obstrução das vias aéreas na DPOC. Neste contexto, os objetivos deste estudo foram: (1) avaliar o comportamento da LFE durante o processo de envelhecimento e (2) estudar a LFE presente nos portadores de DPOC. Trata-se de um estudo transversal controlado com avaliação de casos prevalentes, tendo como unidade de avaliação o indivíduo. Os exames realizados incluíram medidas de espirometria e NEP. Foram selecionados indivíduos saudáveis para o grupo envelhecimento separados em três grupos: grupo jovem (GJ), n=17; grupo meia idade (GMI), n=17 e grupo idoso (GI), n=17. No grupo DPOC foram selecionados indivíduos tabagistas e com doença obstrutiva, sendo classificados de acordo com o nível de obstrução sugerido pela espirometria. Essa classificação resultou em cinco categorias: indivíduos normais ao exame espirométrico (NE, n= 18); com distúrbio ventilatório obstrutivo leve (DVOL, n=15); distúrbio ventilatório obstrutivo moderado (DVOM, n= 18); distúrbio ventilatório obstrutivo acentuado (DVOA, n= 18) e distúrbio ventilatório obstrutivo muito acentuado (DVOMA, n= 18). Todos os indivíduos realizaram os exames de NEP e posteriormente foram submetidos à espirometria. No estudo sobre envelhecimento o parâmetro LFE% foi o que melhor caracterizou a LFE, apresentando uma correlação moderada com a idade. Os parâmetros ∆EF0-50% e ∆EF25-75% apresentaram uma correlação razoável com o progredir da idade, possivelmente devido a LFE no idoso apresentar componentes relacionadas às vias aéreas superiores. No grupo DPOC a NEP caracterizou adequadamente a LFE, sendo o melhor parâmetro a LFE%. Alterações significativas também foram encontradas com os parâmetros ∆EF0-50% e ∆EF25-75%. Avaliando-se a influência da idade neste grupo, pode-se observar que a idade é um fator de contribui para a LFE, no entanto, o efeito preponderante foi a gravidade da doença. Pode-se concluir que: (1) a NEP é útil no estudo da LFE em idosos saudáveis; (2) nestes indivíduos a LFE ocorre principalmente nas vias aéreas extratorácicas; (3) que a NEP é útil na avaliação de pacientes com DPOC, e: (4) que os efeitos da DPOC se sobrepõe ao efeito do envelhecimento.